More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/R-848 [144875-48-9]
Chemical Structure
Chemical Structure
Chemical Structure

R-848 [144875-48-9]

Research Use Only
AG-CR1-3582
AdipoGen Life Sciences
CAS Number144875-48-9
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight314.4
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    R-848 [144875-48-9]
  • Delivery Days Customer
    10
  • CAS Number
    144875-48-9
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C17H22N4O2
  • Molecular Weight
    314.4
  • Scientific Description
    Chemical. CAS: 144875-48-9. Formula: C17H22N4O2. MW: 314.4. Synthetic. Immune response modifier. Potent antitumor and antiviral compound. Stimulates antibody secretion and cytokine production. Used as adjuvant to increase the effectiveness of vaccines. Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human. Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-kappaB. NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I. Upregulator of the opioid growth factor receptor. Used in the treatment of skin lesions such as herpes simplex virus. - Immune response modifier. Potent antitumor and antiviral compound [1, 3, 10, 11, 13, -16]. Stimulates antibody secretion and cytokine production [2]. Used as adjuvant to increase the effectiveness of vaccines [2, 7, 9, 10]. Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human [4-6]. Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-kappaB [4]. NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I [8]. Upregulator of the opioid growth factor receptor [12]. Used in the treatment of skin lesions such as herpes simplex virus [16].
  • SMILES
    CCOCC1=NC2=C(N1CC(C)(C)O)C1=C(C=CC=C1)N=C2N
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod: T.L. Wagner, et al.; Cell Immunol. 191, 10 (1999)
  • Adjuvant activities of immune response modifier R-848: comparison with CpG ODN: J.P. Vasilakos, et al.; Cell Immunol. 204, 64 (2000)
  • The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001)
  • Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
  • Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002)
  • Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8: K.B. Gorden, et al.; J. Immunol. 174, 1259 (2005)
  • TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005)
  • Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3: T.D. Kanneganti, et al.; Nature 440, 233 (2006)
  • Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination: R. Ma, et al.; BBRC 361, 537 (2007)
  • Resiquimod and other immune response modifiers as vaccine adjuvants: M.A. Tomai, et al.; Expert Rev. Vaccines 6, 835 (2007) (Review)